LEGN — Legend Biotech Income Statement
0.000.00%
Last trade - 00:00
- $9.17bn
- $8.22bn
- $285.14m
- 56
- 12
- 45
- 31
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F/A | 20-F/A | 20-F/A | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 60 | 75 | 68.8 | 117 | 285 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 51.6 | 141 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 194 | 385 | 469 | 554 | 813 |
Operating Profit | -134 | -310 | -400 | -437 | -528 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -127 | -308 | -407 | -446 | -520 |
Provision for Income Taxes | |||||
Net Income After Taxes | -102 | -266 | -404 | -446 | -518 |
Net Income Before Extraordinary Items | |||||
Net Income | -102 | -266 | -404 | -446 | -518 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -102 | -266 | -404 | -446 | -518 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.508 | -1.13 | -1.43 | -1.4 | -1.47 |